SLE (SYSTEMIC LUPUS)
Clinical trials for SLE (SYSTEMIC LUPUS) explained in plain language.
Never miss a new study
Get alerted when new SLE (SYSTEMIC LUPUS) trials appear
Sign up with your email to follow new studies for SLE (SYSTEMIC LUPUS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Gene-Edited cells take on lupus and scleroderma in first human test
Disease control Recruiting nowThis early-stage study tests a one-time treatment made from donor immune cells that are gene-edited to target and destroy faulty immune cells causing disease. It is for 80 adults with severe lupus, scleroderma, or myositis that have not responded to standard therapies. The main g…
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated May 26, 2026 06:13 UTC
-
New drug trial aims to tame autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new medicine, SAR448501/DR-0201, in adults with lupus or rheumatoid arthritis. The goal is to find safe and tolerable doses by checking side effects and how the drug works in the body. About 62 participants will receive multiple doses and be followe…
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated May 26, 2026 06:13 UTC
-
Immune reset: CAR-T therapy targets lupus and other autoimmune conditions
Disease control Recruiting nowThis early-stage study tests a new treatment using a patient's own immune cells, modified to target and destroy faulty immune cells causing autoimmune diseases like lupus and scleroderma. The goal is to see if this 'reset' is safe and can control disease activity. About 20 adults…
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 06:12 UTC
-
New lupus drug shows promise in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called CLN-978 in 24 people with moderate to severe systemic lupus erythematosus (SLE). The goal is to see if the drug is safe and how it affects the body, including reducing immune cells linked to the disease. Participants receive the drug…
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated May 26, 2026 06:11 UTC
-
New hope for lupus skin flares: experimental drug VENT-03 enters Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called VENT-03 in 24 adults with active cutaneous lupus (skin lupus), with or without systemic lupus. Participants take VENT-03 or a placebo for 4 weeks, then everyone gets VENT-03 for 8 more weeks. The goal is to see if the drug reduces skin…
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE2 • Sponsor: Ventus Therapeutics U.S., Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC